Featured Research

from universities, journals, and other organizations

Hormone Replacement Therapy Trial Stopped Early After 'Unacceptable Risks' For Women With Previous Breast Cancer

Date:
February 5, 2004
Source:
Harbor-UCLA Research And Education Institute (REI)
Summary:
A Swedish study established to assess the effect of hormone replacement therapy (HRT) for women with a history of breast cancer has been stopped early after preliminary results show 'unacceptably high' risks of breast cancer recurrence for HRT users. The results are published online by THE LANCET (3 February 2004) and will appear in the February 7 print edition.

A Swedish study established to assess the effect of hormone replacement therapy (HRT) for women with a history of breast cancer has been stopped early after preliminary results show 'unacceptably high' risks of breast cancer recurrence for HRT users. The results are published online by THE LANCET (3 February 2004) and will appear in the February 7 print edition.

The increasing survival of women with breast cancer has made the management of menopause (either natural or early-onset due to hormone therapy or chemotherapy) an important clinical issue. The HABITS trial (Hormonal replacement therapy after breast cancer diagnosis--is it safe?) was one of several trials established in the 1990s to assess the possible risk of recurrent breast cancer for women using HRT. Originally planned to include at least 1300 women followed up for five years, the trial was stopped on December 17, 2003, after an average follow-up of just over two years. The steering committee for the trial were concerned that early results from the study showed an unacceptably high risk of recurrent breast cancer for those women randomized to receive HRT; of 345 women (all of whom had had previous breast cancer and were randomized to HRT or no HRT) with at least one follow-up assessment, 26 in the study arm allocated HRT reported a recurrence (or a new case) of breast cancer, compared with seven women who received therapy other than HRT for menopausal symptoms.

In an accompanying Commentary, Rowan T Chlebowski (Harbor-UCLA Research and Education Institute, USA) and Nananda Col (Brigham and Women's Health Hospital, Boston, USA) conclude: "…considering all available evidence about the effect of hormone therapy on breast cancer and chronic disease, the HABITS investigators' conclusion that even short-term use of hormone therapy poses an unacceptably high risk of breast cancer can now reasonably guide clinical practice for women with breast cancer…Alternative safe and effective strategies for the difficult problem of menopausal symptoms in these women now need to be developed".


Story Source:

The above story is based on materials provided by Harbor-UCLA Research And Education Institute (REI). Note: Materials may be edited for content and length.


Cite This Page:

Harbor-UCLA Research And Education Institute (REI). "Hormone Replacement Therapy Trial Stopped Early After 'Unacceptable Risks' For Women With Previous Breast Cancer." ScienceDaily. ScienceDaily, 5 February 2004. <www.sciencedaily.com/releases/2004/02/040203234441.htm>.
Harbor-UCLA Research And Education Institute (REI). (2004, February 5). Hormone Replacement Therapy Trial Stopped Early After 'Unacceptable Risks' For Women With Previous Breast Cancer. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2004/02/040203234441.htm
Harbor-UCLA Research And Education Institute (REI). "Hormone Replacement Therapy Trial Stopped Early After 'Unacceptable Risks' For Women With Previous Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2004/02/040203234441.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins